Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

January 8th 2024

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

November 20th 2023

The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15th 2023

The FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an announcement from Rznomics Inc.

FG001 Meets Detection End Point in High-Grade Glioma

November 14th 2023

The use of the optical imaging agent FG001 led to the detection of additional cancer by optical guidance in patients with high-grade glioma, meeting the primary end point of the phase 2b FG001-CT-001 trial.

VAL-083 Fails to Outperform SOC in Glioblastoma

October 31st 2023

VAL-083 did not improve efficacy compared with standard-of-care approaches in patients with glioblastoma.

FDA Grants Priority Review to Tovorafenib in Pediatric Relapsed/Progressive Low-Grade Glioma

October 30th 2023

The FDA has granted priority review to a new drug application seeking the approval of tovorafenib monotherapy for the treatment of pediatric patients with relapsed or progressive low-grade glioma.

FDA Grants Orphan Drug Designation to TTX101 in Malignant Glioma

October 25th 2023

The FDA has granted an orphan drug designation to TTX101 as a potential therapeutic option for patients with malignant glioma.

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17th 2023

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Grants Fast Track Designation to SurVaxM in Newly Diagnosed Glioblastoma

October 12th 2023

The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.

FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma

October 6th 2023

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

FDA Awards Orphan Drug Designation to FG001 in High-Grade Glioma

October 4th 2023

The FDA has granted an orphan drug designation to FG001 as an optical imaging agent for the visualization of malignant tissue during surgery for patients with high-grade glioma.

ABM-1310 Receives FDA Fast Track Designation for BRAF V600E+ Glioblastoma

September 26th 2023

The FDA has granted fast track designation to ABM-1310 for the treatment of patients with glioblastoma harboring BRAF V600E mutations.

FDA Approves New and Updated Indications for Temozolomide in Anaplastic Astrocytoma

September 14th 2023

The FDA has approved temozolomide (Temodar) for the adjuvant treatment of adult patients with newly diagnosed anaplastic astrocytoma. Under Project Renewal, the regulatory agency has also revised indications for the treatment of patients with refractory anaplastic astrocytoma.

FDA Approval Sought for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma

September 11th 2023

A rolling new drug application seeking the approval of tovorafenib monotherapy for the treatment of patients with relapsed or progressive pediatric low-grade glioma has been submitted to the FDA.

Dr Monga on the Background of Investigating PRT811 in Glioma and Melanoma

August 29th 2023

Varun Monga, MD, discusses the background for investigating the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in a phase 1 study in patients with recurrent high-grade glioma or uveal melanoma, as well as the agent’s mechanism of action.

Vemurafenib Plus Cobimetinib Demonstrates Near 100% Response Rate in Papillary Craniopharyngiomas

August 16th 2023

The combination of vemurafenib and cobimetinib led to a 94% partial response rate or better in 16 patients with newly diagnosed BRAF-mutated papillary craniopharyngiomas.

Berubicin Demonstrates Early Promise in Recurrent or Refractory Glioblastoma Multiforme

August 15th 2023

Berubicin was found to have acceptable tolerability when administered as second-line treatment in patients with recurrent or refractory glioblastoma multiforme.

FDA Awards Orphan Drug Designation to LSTA1 for Malignant Glioma

August 8th 2023

The FDA has granted orphan drug designation to LSTA1 for use as a potential therapeutic option in patients with malignant glioma, according to an announcement from Lisata Therapeutics, Inc.

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

August 7th 2023

Rimas V. Lukas, MD, reflects on the key points of his presentation delivered at the 2023 Best of ASCO Meeting, which comprised existing unmet needs in low-grade glioma, key efficacy and safety findings from the INDIGO trial, and the viability of vorasidenib-based combination regimens for future investigation.

FDA Grants Orphan Drug Designation to ABM-1310 for BRAF V600–Mutant Glioblastoma

August 3rd 2023

The FDA has granted an orphan drug designation to ABM-1310 for the treatment of patients with BRAF V600–mutant glioblastoma.